Canine tumours show varied CB1 and CB2 expression; treatment effects remain…
Differential expression of CB1 and CB2 receptors in canine malignant neoplasms.
AI Summary
This study asked whether CB1 and CB2 gene expression differs among canine malignant tumours. Researchers used real-time quantitative PCR to analyse preserved tumour samples from dogs with squamous cell carcinoma, bladder urothelial carcinoma, mammary carcinoma, melanoma, haemangiosarcoma or osteosarcoma, comparing expression with normal canine brain for CB1 and lymph node for CB2.
CB1 expression was significantly lower than its control in all tumour types except melanoma. CB2 expression was significantly lower in squamous cell carcinoma, bladder urothelial carcinoma, osteosarcoma and mammary carcinoma, but not in melanoma or haemangiosarcoma; expression also differed among tumour types for both receptors. These findings suggest tumour-specific differences in components of the endocannabinoid system, but this gene-expression study cannot establish what the differences mean for tumour behaviour or whether cannabinoid-based treatments would help. This is an abstract-based summary, not a review of the full text.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
In septic rats, lenabasum reduced lung injury markers over 24 hours
Endocannabinoid levels differed in RA and tracked disease activity in women
Lab tests confirmed metabolites, some of which activated CB1
Explore More Research
Stay informed about the latest cannabis science.